Ayala Pharmaceuticals, Inc. (AYLA)
$0.5339
Rating:
Recommendation:
-
| Symbol | AYLA |
|---|---|
| Price | $0.5339 |
| Beta | 0.000 |
| Volume Avg. | 0.05M |
| Market Cap | - |
| Shares () | - |
| 52 Week Range | 0.3568-5.9425 |
| 1y Target Est | - |
| DCF Unlevered | AYLA DCF -> | |
|---|---|---|
| DCF Levered | AYLA LDCF -> | |
| ROE | -308.79% | Strong Sell |
| ROA | -829.80% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -159.33% | Sell |
| P/E | - | |
| P/B | -7.51 | Strong Sell |
Latest AYLA news
About
Download (Excel)Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.